CliffBio
small molecule

DHIVY

CARBIDOPA; LEVODOPA

Loss of exclusivityMarch 2039latest FDA-listed patent expiry
CompanyAvion Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameDHIVY
Active ingredientCARBIDOPA; LEVODOPA
Strength25MG;100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2021
Marketing statusRX

Listed patents

PatentExpiresType
11819485March 2039use U-3557
11439613March 2039use U-3557
11033521March 2039product

More from Avion Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DHIVY patent cliff — loss of exclusivity March 2039 | CliffBio